Revolutionizing Cancer Detection with Plasma Proteomics
Our Unique Approach Works
A novel lens that complements existing diagnostic technologies
HIGH ACCURACY AND REPRODUCIBILITY
Early detection of cancer from liquid biopsies, avoiding need for tissue biopsies
>90%
Accuracy/AUC in Multiple Indications
UNIQUE FINGERPRINTS
OF CANCER
EV plasma subfraction yields differentially expressed biomarkers reflecting a unique view of tumor biology and patient’s response to cancer
~2,000
Proteins ID’d from
our EV Preps
RAPID TRANSLATION TO CLINICAL IMMUNOASSAYS
Mass Spec & Machine Learning workflows define multiplexes for inexpensive, rapid and facile ELISAs
From Hypothesis to Assay
~12 Wks
Application Pipeline
Our Process
EV Technology
Biomarker Discovery
Clinical Translation
Proprietary EV Isolation and Liquid Biopsy
Rapid Pipeline for Machine Learning Driven Proteomic Biomarker Discovery
Translation of Multiplexes into Fast, Distributable Clinical Assays
Our Goal
To Develop Novel Liquid Biopsy Assays To Detect Pre-Cancer and Early Stage Cancer
Why Extracellular Vesicles?
Biological functions of EVs make them ideal to evaluate tumor, tumor microenvironment, and host response biomarkers
Highly abundant, stable circulating particles contain heterogeneous multiomic signals that are compatible with all standard blood collection methods from a small volume
“Cancer isn’t a single disease. Ideal biomarker panels would reflect both tumor and patient responses.”
-Diagnostics VP
“I need simple methods that align with standard clinical practice”
-Pharma VP
Collaborate With Us
Diagnostics Companies
Pharmaceutical Companies
Early Detection, Recurrence and Cancer Staging
Deep Proteomic Biomarker Discovery for Drug Development
Academic Research
Longitudinal Sample
Analysis to Test Your Hypotheses
Executive Team
Todd Hembrough, PhD
Chief Executive Officer
Alan Ezrin, PhD
Board Chairman
J. Carl Barrett, PhD
Director, Advisor
